Androgenic Alopecia TH07 Clinical Trial
ConditionAndrogenic Alopecia
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexMale
Age18-49
SponsorTriple Hair Inc
About this trial
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
Eligibility criteria
Qualifiers
Males, 18 to 49 years of age on the date of enrollment.
Presenting with androgenic alopecia measured as III vertex to V on Hamilton Norwood Scale.
Body Mass Index (BMI) in the range of 19 to 35 kg/m2.
Not administered any systemic or topical treatment for AGA during the last 90 days.
Disqualifiers
Hair transplant or extension surgery.
Hair weaving.
Laser or light therapy on the scalp in the last 6 months.
Micro-needling or intradermal therapy (mesotherapy) on the scalp including PRP in the last 6 months.
Trial design
Treatments tested in this trial
- TH07
- TH07
- Minoxidil 5% Topical Solution
- Placebo
Treatment groups
420 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov